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5AXEL ULLRICH: MOLECULAR MEDICINE 1977-2013
Molecular medicine in the last 45 years means breakthrough research in genom-
ics, proteomics, bioinformatics, antibodies, small molecular drug discovery, high 
throughput screening, signal transduction therapy, targeted therapy, personalized 
therapy and several other related research areas. But the whole story started with 
basic discoveries in genomics and molecular biology where I was lucky enough to 
be involved from the very early stage. 
In the 1970s and 1980s, at a very early stage of  gene technology develop-
ment, with my colleagues at UCSF and Genentech we worked out the Method for 
Producing Recombinant Bacterial Plasmids Containing the Coding Sequences of  
Higher Organisms and we were the fi rst to clone genes of  medically important 
human proteins such as insulin which later in 1985 led to the fi rst gene technol-
ogy-based therapeutic agent – Humulin (Lilly). At UCSF in 1977 we constructed 
the fi rst plasmids containing the coding sequences of  the rat insulin genes1. Based 
on this research already at Genentech I determined the Nucleotide sequence of  
human pre-proinsulin complementary DNA in 1980, which led to the develop-
ment of  Humulin2. We created and patented the recombinant bacterial plasmids 
containing the coding sequence of  insulin genes. 
This research logically led to attempts towards the molecular genetic char-
acterization of  small growth factors like EGF and corresponding cell surface 
1 Ullrich, A., Shine, J., Chirgwin, J., Pictet, R., Tischer, E., Rutter, W.J., and Goodman, H.M. (1977) Rat in-
sulin genes: Construction of  plasmids containing the coding sequences. Science 196 (4296), 1313-1319.
2 Sures, I., Goeddel, D., Gray, A., and Ullrich, A. (1980) Nucleotide sequence of  human preproinsu-
lin complementary DNA. Science 208 (4439), 57-59.
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receptors. The cloning of  cDNA encoding the epidermal growth factor receptor 
(EGFR), what we published in Nature in 1983 3, opened up a research fi eld that is 
known today as “Signal Transduction” research. 
The breakthrough discovery of  Bishop and Varmus that cancer inducing genes 
of  animal retroviruses such as v-src or v-ras represent mutated host genes that were 
recombined into the viral genome raised the question of  whether the oncogene con-
cept was also relevant to human cancer. The fi rst cloning and sequence analysis of  a 
cDNA encoding a cell surface protein, the human EGF receptor, provided a partial 
answer to this question by revealing a close relationship with the v-erb-B oncogene 4, 5.
3 Gray, A., Dull, T.J., and Ullrich, A. (1983) Nucleotide sequence of  epidermal growth factor cDNA 
predicts a 128,000-molecular weight protein precursor. Nature 303 (5919), 722-725.
4 Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, 
J., and Waterfi eld, M.D. (1984) Close similarity of  epidermal growth factor receptor and v-erb-B 
oncogene protein sequences. Nature 307, 521-527.
5 Ullrich, A., Coussens, L., Hayfl ick, J.S., Dull, T.J., Gray, A., Tam, A.W., Lee, J., Yarden, Y., Libermann, 
T.A., Schlessinger, J., Downward, J., Mayes, E.L.V., Whittle, N., Waterfi eld, M.D., and Seeburg, P.H. 
(1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of  the 
amplifi ed gene in A431 epidermoid carcinoma cells. Nature 309 (5967), 418-425.
Fig 1: Similarities between EGFR and v-er-B
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This fi rst connection between a human gene product that regulates normal cell 
proliferation and a viral oncogene strongly suggested that human cancer develop-
ment may also involve abnormalities in the expression and structure of  endogenous 
genes that have regulatory roles in cell proliferation. A search for such genetic aber-
rations in tumor tissues using cDNA probes of  EGFR and an accidentally cloned 
EGFR related gene, termed HER2 (human EGFR-related gene), resulted in the dis-
covery that the gene encoding the HER2/neu receptor tyrosine kinase is amplifi ed 
up to 100 fold in tumor cells of  about 30% of  patients with invasive breast cancer. 
A signifi cant clinical correlation was shown between HER2/neu gene am-
plifi cation and overexpression and parameters of  malignancy, including reduced 
survival and reduced time to relapse, relative to patients with normal receptor 
levels. Along this line we have elucidated the primary structures of  some very 
Fig 2: Human EGF Receptor-Related Receptor HER2/neu
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important Growth Factors by cDNA cloning of  the precursor proteins for EGF, 
NGF, IGF-1 and IGF-26,7.
At the same time this work initiated a new era of  the “war against cancer”. The 
homology of  EGFR and v-erb-B, an established oncoprotein from the avian erythro-
blastosis virus, revealed the potential role of  growth factor receptors in human cancers.
So the fi rst step in the “war against cancer” was the cloning and primary 
structure elucidation of  the fi rst signal transducing cell surface protein, the EGF 
receptor which turned out to be a Growth Factor Receptor Tyrosine Kinase and a 
Proto-Oncogene. This was the fi rst complete characterization of  a human proto-
oncogene (c-erb-B) product with known biological function which was followed 
by the discovery of  EGFR gene amplifi cation in cancer cells. The fi rst identifi ca-
tion of  oncogenic mutations has been recognized to be critical for human cancer,5. 
This work was continued by cloning and characterization of  receptors for 
insulin (IR), PDGF, IGF-1, CSF-1 and SCF which are survival factors for cancer 
cells and by elucidation of  oncogenic mutations in CSF-1 and SCF (kit) receptors. 
With these results we have confi rmed the existence of  animal oncogene-related 
human proto-oncogenes by cloning the human homologs of  v-fms and v-kit and 
thereby, at a very early stage, long before the “fi eld” picked up this track, estab-
6 Ullrich, A., Gray, A., Berman, C., and Dull, T.J. (1983) Human beta-nerve growth factor gene se-
quence highly homologous to that of  mice. Nature 303 (5920), 821-825.
7 Ullrich, A., Berman, C.H., Dull, T.J., Gray, A., and Lee, J.M. (1984) Isolation of  the human insulin-
like growth factor I gene using a single synthetic DNA probe. EMBO J. 3 (2), 361-364.
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lished “cancer targets” for therapy development. All but the IR currently serve as 
targets for cancer drug development8,9,10,11.
Probably the most important result of  this area beside elucidation of  the 
EGFR sequence was the discovery of  the EGFR-related gene, HER2/c-erbB2, 
encoding a putative receptor with an unknown ligand. HER2 turned out to be the 
human homolog of  the oncogene neu which established another “cancer connec-
tion” of  the receptor tyrosine kinase gene family.
The ultimate goal was to fi ght human cancer with new weapons. In 1985 I 
initiated collaboration with Dennis Slamon, an oncologist at UCLA, with the inten-
tion to investigate the occurrence of  animal oncogenes like v-erb-B in human 
tumors. Genomic analysis of  primary human breast tumors with Slamon using 
our cDNA probes - EGFR, HER2, EGF, PDGF, IGF1, IGF2, NGF - led to the 
discovery that the gene encoding HER2 is amplifi ed and overexpressed in 25% 
of  all breast cancers and that HER2 amplifi cation predicts rapid disease progres-
sion. In my laboratory then we developed several monoclonal antibodies against 
HER2, two of  which, MAb 4D5 and 2C4 were subsequently humanized and 
developed by Genentech for therapeutic use. 
8 Ullrich, A., Bell, J.R., Chen, E.Y., Herrera, R., Petruzzelli, L.M., Dull, T.J., Gray, A., Coussens, L., 
Liao, Y-C., Tsubokawa, M., Mason, A., Seeburg, P.H., Grunfeld, C., Rosen, O.M., and Ramachan-
dran, J. (1985) Human insulin receptor and its relationship to the tyrosine kinase family of  onco-
genes. Nature 313 (6005), 756-761.
9 Yarden, Y., Escobedo, J.A., Kuang, W-J., Yang-Feng, T.L., Daniel, T.O., Tremble, P.M., Chen, E.Y., 
Ando, M.E., Harkins, R.A., Francke, U., Fried, V.A., Ullrich, A., and Williams, L.T. (1986) Structure 
of  the receptor for platelet-derived growth factor helps defi ne a family of  closely related growth 
factor receptors. Nature 323 (6085), 226-232.
10 Coussens, L., Van Beveren, C., Smith, D., Chen, E., Mitchell, R.L., Isacke, C.M., Verma, I.M., and 
Ullrich, A. (1986) Structural alteration of  viral homologue of  receptor proto-oncogene fms at 
carboxyl terminus. Nature 320 (6059), 277-280.
11 Yarden, Y., Kuang, W-J., Yang-Feng, T., Coussens, L., Munemitsu, S., Dull, T.J., Schlessinger, J., 
Francke, U., and Ullrich, A. (1987) Human proto-oncogene c-kit: A new cell surface receptor-
tyrosine kinase for an unidentifi ed ligand. EMBO J. 6 (11), 3341-3351.
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The discovery of  the growth factor receptor HER2/neu and the demonstra-
tion of  its major role in mammary cancer progression has become a basic mile-
stone in Target-Specifi c Cancer Therapy and brought along the First Personalized 
Medicine approach. This was achieved by the development of  HER/neu-specifi c 
monoclonal antibody 4D5, which was subsequently humanized to become the 
fi rst cancer genomics-based, personalized, target-specifi c anti-oncogene cancer 
therapeutic -Herceptin- (Genentech Inc. / Hoffmann-La Roche) and has been 
available to breast cancer patients since 1998.
Fig 3: Herceptin: Humanized Anti-HER2 Antibody
Fig 4: Herceptin history
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In 2005 results of  a multi-center trial (HERA) which were reported at 
ASCO demonstrated a major benefi t for HER2 positive breast cancer patients in 
adjuvant therapy preventing tumor recurrence in 46% of  the probands12,13,14, 15, 16.
12 Coussens, L., Yang-Feng, T.L., Liao, Y-C., Chen, E., Gray, A., McGrath, J., Seeburg, P.H., Liber-
mann, T.A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. (1985) Tyrosine kinase recep-
tor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. 
Science 230 (4730), 1132-1139.
13 Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L. (1987) Human 
breast cancer: Correlation of  relapse and survival with amplifi cation of  the HER-2/neu oncogene. 
Science 235 (4785), 177-182.
14 Slamon, D.J., Godolphin, W., Jones, L.A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, 
S.G., Udove, J., Ullrich, A., and Press, M.F. (1989) Studies of  the HER-2/neu proto-oncogene in 
human breast and ovarian cancer. Science 244 (4905), 707-712.
15 Hudziak, R.M., Lewis, G.D., Winget, M., Fendly, B.M., Shepard, H.M., and Ullrich, A. (1989) 
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast 
tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9 (3), 1165-1172.
16 Fendly, B.M., Winget, M., Hudziak, R., Lipari, M.T., Napier, M.A., and Ullrich, A. (1990) Charac-
terization of  murine monoclonal antibodies reactive to either the human epidermal growth factor 
receptor or HER-2/neu gene product. Cancer Res. 50 (5), 1550-1558.
Fig 5: Treatment of  BT474 xenografts with Herceptin and Taxol
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Herceptin (trastuzumab) for the treatment of  metastatic breast cancer and 
Gleevec (imatinib mesylate from Novartis) for the therapy of  patients with Phila-
delphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) are 
the fi rst examples of  gene-based cancer drugs, and represent the most signifi cant 
development toward a new era of  target-directed therapies. These agents not 
only prolong life and improve its quality, they also provide clinical validation of  
the emerging fi eld of  molecular oncology, specifi cally therapies targeting kinase 
enzymes that play a critical role in tumorigenesis and –malignant progression.
Following the prototypical example of  Herceptin, drugs that interfere with 
the disease-promoting functions of  these receptors are currently being developed 
by pharmaceutical companies worldwide. In direct continuation of  his work that 
led to Herceptin we developed MAbs against HER3, a co-signal transducer of  
EGFR and HER2, which is currently in phase II clinical trials by U3 Pharma/
Daiichi-Sankyo17. 
17 Htun-van der Horst, E., Murgia, M., and Ullrich, A. (2005) Anti-HER-3 Monoclonal Antibodies 
Inhibit HER-3-mediated Signaling in Breast Cancer Cell Lines Resistant to Anti-HER-2; Anti-
HER-3 Monoclonal Antibodies in Breast Cancer Therapy. Int. J. Cancer 115 (4), 519-527.
Fig 6: HER3 expression confers poor prognosis for melanoma patients
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In the 20 years since the isolation of  the cDNA encoding the epidermal 
growth factor receptor (EGFR) and the deduction of  its amino-acid sequence, 
intensive research efforts have led to important insights into the molecular mech-
anisms of  receptor tyrosine kinase (RTK) function and involvement in cancer. 
Moreover, substantial advances have been made in understanding the key 
roles of  RTKs in the signaling pathways that govern fundamental cellular pro-
Fig 7: Proliferation and invasion inhibition by HER3maB 2D1D12
14 SZÉKFOGLALÓK A MAGYAR TUDOMÁNYOS AKADÉMIÁN
cesses, such as proliferation, migration, metabolism, differentiation and survival, as 
well as those that regulate intercellular communication during development. RTK 
activity in resting, normal cells is tightly controlled. When these genes are mutated 
or structurally altered, however, RTKs become potent oncoproteins: abnormal 
activation of  RTKs in transformed cells has been shown to be causally involved in 
the development and progression of  many human cancers. Consequently, RTKs 
and their growth-factor ligands have become rational targets for therapeutic in-
tervention using humanized antibodies and small molecule drugs. In recent years, 
RTK-based cancer therapies — for example, for the treatment of  metastatic breast 
cancer, kidney cancer, gastrointestinal stromal tumors and non-small cell lung can-
Fig 8: Anti-HER3 antibodies inhibit HER3 activation and melanoma cell proliferation
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cer — h a v e 
Fig 9: Anti-HER3 antibody 105.5 inhibits melanoma cell migration and invasivity
Fig 10: human anti-HER3 mAb inhibits ligand-induced HER3 activation
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reached widespread clinical use and have thereby demonstrated the power of  
gene-based therapy development 18.
The strategy of  genomics-based, target-driven drug development has revo-
lutionized medicine and has led to new “bullets in the war against cancer” like 
18 Gschwind, A., Fischer, O. M. and Ullrich, (2004) A. The discovery of  receptor tyrosine kinases: 
targets for cancer therapy Nature Reviews Cancer 4: 361-370.
Fig 11: Treatment with human anti-HER3 mAb signifi cantly reduces pHER3 levels in BxPC-3 tumor xenografts
Fig 12: Treatment with human anti-HER3 mAbs results in inhibition of  BxPC-3 pancreatic carcinoma xenografts
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Gleevec, Iressa, Tarceva, Nexavar and others. Analogous approaches towards 
“Personalized Signal Transduction Therapies for Cancer” are now being pursued 
by hundreds of  academic and industrial laboratories worldwide.
In the 1990s after moving to the Max Planck Institute of  Biochemistry in 
Martinsried (Germany) I continued to initiate the development of  yet more ef-
Fig 13: RTK subclasses
Fig 14: Future of  individualized cancer therapy
18 SZÉKFOGLALÓK A MAGYAR TUDOMÁNYOS AKADÉMIÁN
fi cacious cancer therapies by further exploring the signifi cance of  the phospho-
tyrosine signaling system and the kinases controlling it. 
We have discovered and functionally characterized the receptor tyrosine ki-
nase Flk-1/VEGFR2 as an essential element of  the process of  tumor angiogenesis 
and by this fi nding have initiated another important strategy for cancer therapy. 
We demonstrated that blocking this receptor in a rat brain tumor model re-
sulted in signifi cantly impaired tumor growth. This anti-angiogenic approach was 
subsequently brought to clinical application by Sugen Inc., a biotech company 
co-founded by me. Collaborating with György Kéri’s company Biosignal utilizing 
his library we have identifi ed the chemical structures of  oxindols which strongly 
inhibit the Flk-1/VEGFR2 kinase. 
The identifi cation of  Flk-1/VEGFR2 as the critical receptor for the develop-
ment of  the vascular system and for tumor angiogenesis and the identifi cation of  
its chemical inhibitors (in close collaboration with Alex Levitzki of  Hebrew Univer-
sity and György Kéri of  Vichem Ltd. ) resulted in the development of  the target-
specifi c (Flk-1/VEGFR2) anti-angiogenic drug (SU5416) and the multi-targeted 
drugs SU6668 and SU11248 by SUGEN, Inc. for the treatment of  various cancers.
SU11248 (SUTENT) was submitted in July 2005 (Pfi zer) to the FDA for ap-
proval for the treatment of  Gleevec-resistant Gastrointestinal Stromal Tumors (GIST).
Fig 15: From mono- to multi-targeted kinase inhibitors
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SU11248/SUTENT/Sunitinib, the fi rst “designed” multi-targeted cancer 
drug (Pfi zer), was approved on January 26, 2006 for the treatment of  GIST and Re-
nal Cell Carcinoma by the FDA and in July 2006 by the European EMEA 19, 20, 21,22,23.
19 Millauer, B., Shawver, L.K., Plate, K.H., Risau, W., and Ullrich, A. (1994) Glioblastoma growth 
inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367 (6463), 576-579.
20 Millauer, B., Longhi, M.P., Plate, K.H., Shawver, L.K., Risau, W., Ullrich, A., and Strawn, L.M. 
(1996) Dominant-negative inhibition of  Flk-1 suppresses the growth of  many tumor types in vivo. 
Cancer Res. 56 (7), 1615-1620.
21 Strawn, L.M., McMahon, G., App, H., Schreck, R., Kuchler, W.R., Longhi, M.P., Hui, T.H., Tang, C., 
Levitzki, A., Gazit, A., Chen, I., Kéri, G., Orfi ,, L., Risau, W., Flamme, I., Ullrich, A., Hirth, K.P. and 
Shawver, L.K. (1996) Flk-1 as a Target for Tumor Growth Inhibition. Cancer Res. 56 (15), 3540-3545.
22 Fong, T.A.T., Shawver, L.K., Sun, L., Tang, C., App, H., Powell, T.J., Kim, Y.H., Schreck, R., Wang, X.Y., 
Risau, W., Ullrich, A., Hirth, K.P., and McMahon, G. (1999) SU5416 is a potent and selective Inhibi-
tor of  the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) that Inhibits Tyrosine Kinase 
Catalysis, Tumor Vascularization, and Growth of  Multiple Tumor Types. Cancer Res. 59 (1), 99-106.
23 Laird, A.D., Vajkoczy, P., Shawver, L.K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., 
Ullrich, A., Hubbard, S.R., Blake, R.A., Fong, A.T., Strawn, L.M., Sun, L., Tang, C., Hawtin, R., Tang, 
F., Hirth, K.P., McMahon, G., and Cherrington, J. (2000) SU6668 is a potent Anti-Angiogenic and 
Anti-Tumor Agent that Induces Regression of  Established Tumors. Cancer Res. 60 (15), 4152-4160.
Fig 16: Sunitinib in metastatic RCC
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Sunitinib represents a prototype multi-targeted therapeutic that promises to 
be effi cacious in many different cancers as recently shown for neuroendocrine 
pancreatic tumors. 
Further exploring the signifi cance of  the phospho-tyrosine signaling system 
and the kinases controlling it we have validated the Axl/Ufo Receptor Tyrosine 
Kinase as a Cancer Drug Development Target and discovered that this tyrosine 
kinase is a major metastasis-promoting cell surface signal transducer in Glioma, 
Fig 17: Sutent history
Fig 18: Sutent
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breast cancer 24 and other cancers. To identify the genes that mediate progres-
sion of  breast cancer we have focused on key elements of  the phosphor-protein-
24 Vajkoczy, P., Knyazev, P., Kunkel, A., Capelle, H.-H., Behrndt, S., von Tengg-Kobligk, H., 
Kiessling, F., Eichelsbacher, U., Knyazev, P., Essig, M., Read, T.-A., Erber, R., and Ullrich, A. (2006) 
Fig 19: Target-identifi cation via affi nity chromatography and mass spectrometry
Fig 20: Kinase affi nity spectrum in cancer cell lines
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Dominant-negative Inhibition of  the Axl Receptor Tyrosine Kinase Suppresses Brain Tumor Cell 
Growth and Invasion, and Prolongs Survival. Proc. Natl. Acad. Sci. 103 (15), 5799-5804.
Fig 21: Sutent-responsive RTKs
Fig 22: Sunitinib acts on angiogenesis and tumor cells
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mediated signaling system because of  its established role in human cancer. After 
systematically analyzing expression profi les of  kinases of  13 weakly invasive and 
8 highly invasive breast cancer cell lines and normal mammary epithelia cell lines 
by cDNA array hybridization analysis, we identifi ed a cluster of  genes character-
istic for highly invasive cell types. The RTK AXL was part of  the gene cluster, 
predictive of  the aggressiveness of  breast cancer cells.
The mammalian AXL RTK subfamily includes three closely related mem-
bers: AXL, SKY, and MER. GAS6, originally isolated as a growth arrest–specifi c 
gene, is the common ligand for AXL subfamily receptors. GAS6-AXL signaling 
has been implicated in a host of  discrete cellular responses including cell survival, 
proliferation, migration, and adhesion. 
Fig 23: Gas/AXL system
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AXL expression has been reported in a wide variety of  human can-
cers15,16,17,19,24,25.
 Especially in breast cancer patients, a signifi cant correlation was found be-
tween AXL and tumor stage15. Moreover, some reports indicated that AXL might 
be involved in cancer progression20,21. These prompted us to further investigate 
the role of  AXL in breast cancer. Experimental inhibition of  AXL signaling by a 
dominant-negative AXL mutant, an antibody against the extracellular domain of  
AXL, or short hairpin RNA knockdown of  AXL decreased motility and invasiv-
ity of  highly invasive breast cancer cells. 
To selectively interfere with cancer cell properties defi ning the rate of  disease 
progression we identifi ed 3-quinolinecarbonitrile compounds, which displayed 
potent inhibitory activity against AXL and showed strong interference with mo-
tility and invasivity of  breast cancer cells. Our fi ndings validated the RTK AXL as 
Fig 24: Identifi cation of  AXL as a gene characteristic for invasive breast cancer
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a critical element in the signaling network that governs motility and invasivity of  
breast cancer cells, and allowed the identifi cation of  experimental anti-AXL small 
molecular inhibitors in collaboration with G. Kéri, L. Orfi  and Vichem Chemie 
that represent lead substances for the development of  antimetastatic breast can-
cer therapy 25.
We have shown that AXL has an important role in mediating breast cancer 
cell motility and invasivity. Moreover, we identifi ed 3-quinolinecarbonitrile com-
pounds that displayed potent inhibitory activity against AXL, and showed strong 
interference with motility and invasivity of  breast cancer cells. We have developed 
a series of  very potent and drug like Axl kinase inhibitors which are now in pre-
clinical development.
We have also analyzed the Cellular Signaling Networks in Cancer Cells and 
discovered and characterized the G-protein-coupled EGF Receptor Transactiva-
25 Zhang, Y., Knyazev, P. G., Cheburkin, Y. V., Sharma, K., Knyazev, Y. P., Örfi , L., Szabadkai, I., 
Daub, H., Kéri, G., and Ullrich, A. (2008) AXL Is a Potential Target for Therapeutic Intervention 
in Breast Cancer Progression. Cancer Research 68 (6), 1905-1915.
Fig 25: Screening for AXL inhibitors
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tion pathway in normal and cancer cells and demonstrated that physiological fac-
tors like LPA, Angiotensin II, Endothelin and others may be involved in cancer 
progression26,27,28,29,30. 
In a novel approach with the discovery of  a frequent polymorphism in the 
transmembrane domain of  the FGFR4 we embarked on an ambitious cancer 
genomics endeavour – the investigation of  the impact of  SNPs on cancer pro-
gression, susceptibility, resistance and therapy response. With his discovery of  
the frequent (50%) FGFR4 388R allele and demonstration of  its progression-en-
hancing effect on breast-, colon, lung and other cancers we have moved towards 
a new frontier of  individualized multi-specifi c cancer diagnosis and therapy. Via 
demonstrating the prognostic signifi cance of  the FGFR4Arg388 allele for breast- 
26 Daub, H., Weiss, F.U., Wallasch, C. and Ullrich, A. (1996) Role of  transactivation of  the EGF recep-
tor in signaling by G-protein-coupled receptors. Nature 379 (6565), 557-560.
27 Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R. Wallasch, C. and Ullrich, A (1999) EGF 
receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of  
proHB-EGF. Nature 402 (6764), 884-888
28 Schäfer, B., Gschwind, A., and Ullrich, A. (2004) Multiple G-Protein-Coupled Receptor Signals 
Converge on the Epidermal Growth Factor Receptor to Promote Migration and Invasion. Oncogene 
23 (4), 991-999.
29 Fischer, O.M., Hart, S., Gschwind, A., Prenzel, N., and Ullrich, A. (2004) Oxidative and Osmotic 
Stress Signaling in Tumor Cells is Mediated by ADAM Proteases and HB-EGF. Mol. Cell Biol. 24 
(12), 5172-5183.
30 Schäfer, B., Marg, B., Gschwind, A., and Ullrich, A. (2004) Distinct ADAM Metalloproteinases 
Regulate G Protein Coupled Receptor-Induced Cell Proliferation and Survival. J. Biol. Chem. 279 
(46), 47929-47938.
Derivative of NA80×1 with Stronger Inhibitory Activity on Axl Phosphorylation, Migration and Invasion
SKI-606



















Fig 26: Development of  SKI-606
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Fig 27: Inhibitory effects of  SKI-606 on the phosphorylation of  AXL
Fig 28: Cellular specifi city profi le of  compounds VI17525 and VI17614
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Fig 29: Inhibitory effects of  NA80x1 on the phosphorylation of  AXL
Fig 30: The EGFR family signaling network
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and colon cancer patients we have established FGFR4 as an intervention target 
for cancer therapy18,31,32,33. 
We have shown that FGFR4 gene expression is up-regulated in doxorubicin-
treated, apoptosis resistant cancer cell clones. Ectopic expression of  FGFR4 in 
cancer cells led to reduced apoptosis sensitivity on treatment with doxorubicin or 
cyclophosphamide, whereas knockdown of  endogenous FGFR4 expression in 
breast cancer cell lines had the opposite effect. FGFR4 overexpression resulted 
in Bcl-xl up-regulation at both mRNA and protein levels. Knockdown of  FGFR4 
expression by small interfering RNA caused a decrease in phospho-extracellular 
signal-regulated kinase1/2 levels and reduced Bcl-xl expression. 
Fibroblast growth factor receptor-4 (FGFR4) is a tyrosine kinase with a 
range of  important physiological functions. However, it is also frequently mu-
tated in various cancers and is now generating signifi cant interest as a potential 
therapeutic target. Unfortunately, biochemical characterization of  its role in dis-
ease and further evaluation as a drug target is hampered by lack of  a specifi c 
inhibitor. We aimed to discover new inhibitors for FGFR4 using a strategy com-
bining in silico, in vitro and cell-based assays. We used the homologous FGFR1 
to calculate docking scores of  a chemically-diverse library of  approximately 2000 
potential kinase inhibitors.
31 Bange, J., Prechtel, D., Cheburkin, Y., Specht, K., Harbeck, N., Schmitt, M., Knyazeva, T., Müller, 
S., Gärtner, S., Sures, I., Wang, H., Imyanitov, E., Häring, H.U., Knyazev, P., Iacobelli, S., Höfl er, H. 
and Ullrich, A. (2002) Cancer progression and tumor cell motility are associated with the FGFR4 
Arg388 allele. Cancer Res. 62 (3), 840-847.
32 Thussbas, C., Nährig, J., Streit, S., Bange, J., Seebauer, M., Kates, R., Ulm, K., Kiechle, M., Höfl er, 
H., Ullrich, A., and Harbeck, N. (2006) FGFR4 Arg388 Allele is Associated with Resistance to 
Adjuvant Therapy in Primary Breast Cancer. J. Clin. Oncol. 24 (23), 3747-55.
33 Streit, S., Mestel, D.S., Schmidt, M., Ullrich, A., and Berking, C. (2006) FGFR4 Arg388 Allele Cor-
relates with Tumor Thickness and FGFR4 Protein Expression with Survival of  Melanoma Patients. 
Br. J. Cancer 94 (12), 1979-1886.
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Fig 31: Docking poses of  representative structures
Fig 32: Identifi ed pharmacophore points
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Nineteen potential inhibitors and ten randomly selected negative controls 
were taken forward for in vitro FGFR4 kinase assays. All compounds with good 
docking scores signifi cantly inhibited FGFR4 kinase activity, some with sub-mi-
cromolar potency (most potent being V4-015 with an IC50 of  0.04 μM). Four of  
these compounds also demonstrated substantial activity in cellular assays using 
the FGFR4-overexpressing breast carcinoma cell line, MDA-MB453. 
Through immunoblot assays these compounds were shown to block the phos-
phorylation of  the FGFR4 adaptor protein, FGFR substrate protein-2 (FRS2).
The most potent compound to date, V4-015, suppressed proliferation of  
MDA-MB453 cells at sub-micromolar concentrations, activated the pro-apoptot-
ic caspases 3/7 and inhibited cellular migration. 
While achieving complete selectivity of  this compound for FGFR4 will re-
quire further lead optimization, this study has successfully identifi ed new chemi-
cal scaffolds with unprecedented FGFR4 inhibition capacities that will support 
mechanism of  action studies and future anti-cancer drug design.
Fig 33: FGFR4 phosphorylation is inhibited by various compounds in MDA-MB453 cells
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Summarising our results in molecular medicine between 1977 and 2013 
we have pioneered the translation of  genomics-based discoveries into novel ap-
proaches for the treatment of  major diseases such as Cancer and Diabetes. With 
two cancer therapeutics and one for the treatment of  diabetes that have emerged 
from this scientifi c work and several promising translational programs under de-
velopment we have made signifi cant contributions to the fi eld of  translational 
medical research worldwide.
Fig 34: FRS2α phosphorylation is reduced by potential FGFR4 inhibitors in MDA-MB453 cells
Fig 35: V4-015 induces apoptosis and inhibits cell migration in breast cancer cell lines
